Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q32 Bio Inc. Director's Dealing 2018

Mar 27, 2018

34891_dirs_2018-03-27_795a09af-f7a7-4aa0-b90d-f723017c405a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: Smith W Bradford (CFO, Treasurer & Secretary)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option $0.64 2027-04-05 Common Stock (163404) Direct
Employee Stock Option $6.64 2027-12-07 Common Stock (63497) Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017.

F2: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018.